Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) shares gapped down before the market opened on Thursday . The stock had previously closed at $24.68, but opened at $23.50. Chugai Pharmaceutical shares last traded at $24.96, with a volume of 2,438 shares.
Chugai Pharmaceutical Stock Performance
The company has a fifty day moving average of $26.58 and a two-hundred day moving average of $24.29. The company has a market cap of $80.50 billion, a PE ratio of 30.20 and a beta of 0.66.
Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported $0.19 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 21.71% and a net margin of 33.56%. The company had revenue of $1.89 billion for the quarter. On average, equities analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current year.
Chugai Pharmaceutical Company Profile
(
Get Free Report)
Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.
Featured Articles
Before you consider Chugai Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chugai Pharmaceutical wasn't on the list.
While Chugai Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
